Vredenburgh, J. J., Desjardins, A., Reardon, D. A., Peters, K., Kirkpatrick, J., Herndon, J. E., … Friedman, H. S. (2010). Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology, 28(15_suppl), 2023–2023. https://doi.org/10.1200/jco.2010.28.15_suppl.2023

Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, and H. S. Friedman. “Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2023–2023. https://doi.org/10.1200/jco.2010.28.15_suppl.2023.

Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, et al. Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 2010 May 20;28(15_suppl):2023–2023.

Vredenburgh, J. J., et al. “Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 2023–2023. Crossref, doi:10.1200/jco.2010.28.15_suppl.2023.

Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S, Friedman HS. Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):2023–2023.